USC School of Pharmacy Associate Professor Julio Camarero is getting support for his studies.
The research funded by a four-year, $1.3 million RO1 grant from the National Institutes of Health focuses on the screening and selection of a novel class of protein-based therapeutics, also known as cyclotides.
Camarero previously has worked to evaluate millions of compounds and to identify those with the best potential to bind and inhibit targets. The process has many applications since it allows for broad-range screening and altering of their structures to better target proteins.
He has published more than 90 articles on his work in peer-reviewed journals. Most recently, his work on cyclotides was featured as the cover story of the July 13 international edition of Angewandte Chemie.